Tech Stock News
Monday, March 27, 2023
Salarius Pharmaceuticals Inc (NASDAQ: SLRX) embark on a clinical trial that seeks to investigate a novel lysine-specific demethylase 1 (LSD1) inhibitor called seclidemstat. This biopharmaceutical company has, over the years, focused n the development of working medicines to help out persons struggling with solid tumors, pediatric cancers, and other cancers. Conducting […]
Salarius Pharmaceuticals Inc (NASDAQ: SLRX) exited yesterday at $1.22, up 0.83%. SLRX has been in the green zone for a long time, and here’s why. Investors responding well to key findings from seclidemstat’s clinical research SLRX, the clinical-stage biopharmaceutical company, is known for developing treatments for cancers, solid tumors, and […]
Salarius Pharmaceuticals Inc (NASDAQ: SLRX) closed at $1.21 on Friday, down 13.57%. Three analysts are covering this stock at the moment, all of who suggest a rating of “Strong Buy.” This stock has a target price that ranges between $5 and $3.8, while the average price target is $4.43. There […]